Feasibility Analysis of Cell-Free DNA Derived from Plasma of Lung Cancer Patients for Next-Generation Sequencing

2020 ◽  
Vol 18 (2) ◽  
pp. 117-121 ◽  
Author(s):  
Xueli Jiang ◽  
Hui Li ◽  
Jingjing Liu ◽  
Heping Sun ◽  
Linna Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Cancer Patients ◽  
Feasibility Analysis ◽  
Next Generation ◽  
Cell Free Dna ◽  
Lung Cancer Patients ◽  
Free Dna ◽  
Generation Sequencing

Spectrum of Pathogenic Germline Mutations in Chinese Lung Cancer Patients through Next-Generation Sequencing

2019 ◽  
Vol 26 (1) ◽  
pp. 109-114 ◽  
Author(s):  
Panwen Tian ◽  
Xiangyang Cheng ◽  
Zhengyi Zhao ◽  
Yuzi Zhang ◽  
Celimuge Bao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Cancer Patients ◽  
Germline Mutations ◽  
Next Generation ◽  
Lung Cancer Patients ◽  
Generation Sequencing

scholarly journals Cell free DNA analysis by SiRe® next generation sequencing panel in non small cell lung cancer patients: focus on basal setting

2017 ◽  
Vol 9 (S13) ◽  
pp. S1383-S1390 ◽  
Author(s):  
Pasquale Pisapia ◽  
Francesco Pepe ◽  
Riccardo Smeraglio ◽  
Maria Russo ◽  
Danilo Rocco ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Dna Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Free Dna ◽  
Generation Sequencing

Next-generation sequencing in metastatic lung cancer patients: Translation from sequence data into clinical practice.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e12521-e12521
Author(s):  
Jessica Ribeiro Gomes ◽  
Raphael Brandao Moreira ◽  
Renata D'Alpino D'Alpino ◽  
Marcelo Rocha S Cruz ◽  
Tercia Tarciane Soares de Sousa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Practice ◽  
Next Generation Sequencing ◽  
Cancer Patients ◽  
Sequence Data ◽  
Metastatic Lung Cancer ◽  
Next Generation ◽  
Lung Cancer Patients ◽  
Metastatic Lung ◽  
Generation Sequencing

scholarly journals Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Julie A. Vendrell ◽  
Sylvie Taviaux ◽  
Benoît Béganton ◽  
Sylvain Godreuil ◽  
Patricia Audran ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Cancer Patients ◽  
Next Generation ◽  
Lung Cancer Patients ◽  
Fusion Transcripts ◽  
Generation Sequencing

scholarly journals Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing

2020 ◽  
Vol 52 (2) ◽  
pp. 543-551 ◽  
Author(s):  
Eunhyang Park ◽  
Hyo Sup Shim
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Cancer Patients ◽  
Single Gene ◽  
Advanced Stage ◽  
Next Generation ◽  
Lung Cancer Patients ◽  
Advanced Stage Lung Cancer ◽  
Generation Sequencing ◽  
Stage Lung Cancer

PurposeEpidermal growth factor receptor (<i>EGFR</i>), anaplastic lymphoma kinase (<i>ALK</i>), and ROS proto-oncogene 1 (<i>ROS1</i>) are ‘must-test’ biomarkers in the molecular diagnostics of advanced-stage lung cancer patients. Although single-gene assays are currently considered the gold standard for these genes, next-generation sequencing (NGS) tests are being introduced to clinical practices. We compared the results of current diagnostics and aimed to suggest timely effective guidance for their clinical use. Materials and MethodsPatients with lung cancer who received both conventional single-gene assays and subsequent targeted NGS testing were enrolled, and the results of their tests were compared. ResultsA total of 241 patients were enrolled, and the <i>EGFR</i> real-time polymerase chain reaction, <i>ALK</i> fluorescence <i>in situ</i> hybridization (FISH), and <i>ROS1</i> FISH assays exhibited 92.9%, 99.6%, and 99.5% concordance with the NGS tests, respectively. The discordant cases were mostly false-negatives of the single-gene assays, probably due to technical limitation. Of 158 cases previously designated as wild-type, <i>EGFR</i>, <i>ALK</i>, and <i>ROS1</i> alterations were identified in 10.1%, 1.9%, and 1.3%, respectively, and other targetable alterations were identified in 36.1% of the cases. Of patients with additionally identified actionable alterations, 32.6% (31/95) received matched therapy with a clinical benefit of 48.4% (15/31). ConclusionEven though the conventional and NGS methods were concordant in the majority of cases, NGS testing still revealed a considerable number of additional <i>EGFR</i>, <i>ALK</i>, and <i>ROS1</i> alterations, as well as other targetable alterations, in Korean advanced-stage lung cancer patients. Given the high frequency of <i>EGFR</i> and other targetable mutations identified in the present study, NGS testing is highly recommended in the diagnosis of Korean lung cancer patients.

Sign in / Sign up

Export Citation Format

Share Document